# Commit Biologics

> Aarhus University spinout designing antibodies that enlist the complement immune system to eliminate selected cancer or autoimmune-disease cells.

## Why it is interesting

November 17, 2026 was a €54M total Seed final close, not €54M of additional November capital. COM002 is preclinical; first patient dosing is targeted for early 2028 and clinical efficacy is unproven.

## Profile

- **Latest funding:** Seed final close (aggregate including older tranches) — €54M total Seed; incremental final-close proceeds undisclosed (November 17, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** Not publicly disclosed
- **Stage:** seed
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-18
- **Latest funding investors:** Ackermans & van Haaren, AbbVie Ventures, M Ventures, Novo Holdings, Bioqube Ventures, Korys

## Key facts

- €54M total Seed financing at November 17, 2026 final close; this amount includes earlier €16M and €5.5M Seed tranches.
- COM002 first candidate nominated November 12, 2026, first patient dosing planned early 2028.
- 2025 primate proof-of-concept is company-reported preclinical data, not demonstrated clinical benefit.

## Funding history

- Seed final close (aggregate including older tranches) · €54M total Seed; incremental final-close proceeds undisclosed · November 17, 2026
  Source: https://commitbio.com/commit-biologics-announces-final-close-of-60-million-seed-financing-to-advance-complement-powered-immune-engagers-toward-the-clinic
- Seed extension (historical incremental tranche) · €5.5M incremental; €21.5M Seed total at that date · January 28, 2025
  Source: https://commitbio.com/commit-biologics-announces-e5-5m-seed-financing-extension-investment-by-korys-to-further-develop-its-bispecific-complement-engaging-bice-platform
- Seed first disclosed tranche (historical) · €16M (part of €54M cumulative Seed) · May 9, 2024
  Source: https://commitbio.com/commit-biologics-launches-with-e16m-seed-financing-to-pioneer-complement-system-activation-to-treat-cancer-and-autoimmune-disease

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 18, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/commit-biologics
